LINKEDIN

TWITTER

A LIFE-SCIENCE CONSULTANCY

Accelerating Access

To Innovative Healthcare Technologies

schedule a meeting
Recent Case Studies

Leadership for Change

Toolsets to Accelerate Access

Evidence Infiltration

Diffusion

Welcome to Syenza

Innovative healthcare technologies improve health, when accessible!

A future of vibrant health awaits, but access barriers are complex and seem insurmountable. Syenza  advances access with our HEOR, Global Market Access,  and Dynamic Intelligence scientific services for Pharmaceutical, Medtech, and Biotech businesses. Simply put, value science is how we accelerate access to innovations that improve health.

MEET OUR TEam

Our Services

Our vision to accelerate access is propelled by three, distinct service dimensions – HEOR, Global Market Access, and Dynamic Intelligence Services. Inspiration, specialization and passion define what we do to
support our clients in the Pharma, Medtech, and Biotech industry.

DYNAMIC INTELLIGENCE

GLOBAL MARKET ACCESS

HEOR

Dedicated and knowledgeable team with a high interest in delivering value adding outcomes. You kept us updated each step of the way.

Global Public Affairs Director, Pharma Company

Insight into proposed projects, and management of timelines and deliverables. Having articles on outcomes of project once project is completed.

Managing Director, MedTech Company

Expertise in the field, communication and constant project status reporting. The team was efficient and easy to work with.

Global Market Access Executive, Pharma Company

Self initiative to take the best path and overcome issues without seeking directions from us every time – saves everyone a lot of time and helps with timelines.

Regional Market Access Director, Pharma Company

Syenza’s vast knowledge and international experience was indispensible around the key issues we sought assistance!

Chief Operating Officer, Pharma Company

Excellence is certainly at the centre of everything you guys do, I see that now. Thanks for making this easier for us!

Public Affairs Director, MedTech Company

What do our clients value most about working with Syenza?

Syenza promptly identifies our needs and delivered appropriate services
1
Syenza is dependable
1
Syenza accurately executes activities at the highest standard
1
Syenza provides individualised and culturally intelligent services
1

We've come a long way

Laozi said a journey of a thousand miles begins with a single step. Our first step started in
January 2008 and along the way we’ve acquired the experience and expertise to
accelerate access to innovative healthcare technologies.

OCTOBER 2022
We publish the world's first budget-impact analysis on a novel medical device with economic benefits for payors.
DECEMBER 2021
We further expand the team, and publish the first budget-impact analysis of its kind in the Middle East.
NOVEMBER 2022
Results of our cost-effectiveness analysis on novel treatments continue to go global influencing major stakeholders.
APRIL 2018
We introduce the first fully online applied pharmacoeconomic course attended by hundreds in SSA and MENA.
SEPTEMBER 2016
Our team expands to support a new Client Charter and clients include Top Pharma and MedTech companies.
JANUARY 2008
Our Founder starts consulting at the WHO and Harvard Medical School after receiving his Ph.D. at Northeastern University.
JUNE 2017
Our health economic projects cover various cancers, CVD, rheumatoid arthritis, epilepsy, multiple sclerosis, & HIV/AIDS.
JUNE 2015
We strengthen our market access and health economic services for pain management and rare diseases.
SEPTEMBER 2019
Our impact grows with HEOR and global market access services for market-leading Medtech companies in Europe, MENA, and SSA.
MARCH 2011
Prominent consulting firms and universities in the US & Europe outsource their HEOR, global market access projects, and research projects

JANUARY 2008

Our Founder starts consulting at the WHO and Harvard Medical School after receiving his Ph.D. at Northeastern University.

MARCH 2011

Prominent consulting firms and universities in the US & Europe outsource their HEOR, global market access projects, and research projects

JUNE 2015

We strengthen our market access and health economic services for pain management and rare diseases.

SEPTEMBER 2016

Our team expands to support a new Client Charter and clients include Top Pharma and MedTech companies.

APRIL 2018

We introduce the first fully online applied pharmacoeconomic course attended by hundreds in SSA and MENA.

JUNE 2017

Our health economic projects cover various cancers, CVD, rheumatoid arthritis, epilepsy, multiple sclerosis, & HIV/AIDS.

SEPTEMBER 2019

Our impact grows with HEOR and global market access services for market-leading Medtech companies in Europe, MENA, and SSA.

DECEMBER 2021

We further expand the team, and publish the first budget-impact analysis of its kind in the Middle East.

NOVEMBER 2022

Results of our cost-effectiveness analysis on novel treatments continue to go global influencing major stakeholders.

OCTOBER 2022

We publish the world’s first budget-impact analysis on a novel medical device with economic benefits for payors.

...and we keep growing

our growth is driven by our singular focus on accelerating access to innovative healthcare technologies
partner with us
Schedule a meeting

Directors Digest

Click here

NICE Approves Belantamab Mafodotin for Multiple Myeloma

Click here

Maximising Efficiency with AI in Clinical Trials

View All

Dive-in to Our Insights

EXPLORE ALL INSIGHTS

Colorectal Cancer: Innovations and Future Strategies

April 1, 2025

Colorectal Cancer: Innovations and Future Strategies

Colorectal cancer (CRC) remains a critical global health concern, ranking as the third most common cancer and the second leading cause of cancer-relat

CVD Innovations Transforming Health

March 13, 2025

CVD Innovations Transforming Health

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, claiming millions of lives annually and presenting significant challenges

A Global Perspective on Innovations in Cervical Cancer

January 30, 2025

A Global Perspective on Innovations in Cervical Cancer

Introduction Cervical cancer remains a significant public health challenge, particularly in low- and middle-income countries (LMICs), where access to